Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Free Cash Flow (2016 - 2025)

Anaptysbio (ANAB) has disclosed Free Cash Flow for 10 consecutive years, with $97.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 246.08% year-over-year to $97.9 million, compared with a TTM value of $19.6 million through Dec 2025, up 114.45%, and an annual FY2025 reading of $19.6 million, up 114.45% over the prior year.
  • Free Cash Flow was $97.9 million for Q4 2025 at Anaptysbio, up from -$27.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $97.9 million in Q4 2025 and bottomed at -$67.0 million in Q4 2024.
  • Average Free Cash Flow over 5 years is -$17.9 million, with a median of -$23.7 million recorded in 2021.
  • The sharpest move saw Free Cash Flow crashed 352.38% in 2022, then skyrocketed 246.08% in 2025.
  • Year by year, Free Cash Flow stood at -$25.3 million in 2021, then soared by 57.1% to -$10.9 million in 2022, then plummeted by 218.87% to -$34.6 million in 2023, then plummeted by 93.55% to -$67.0 million in 2024, then surged by 246.08% to $97.9 million in 2025.
  • Business Quant data shows Free Cash Flow for ANAB at $97.9 million in Q4 2025, -$27.3 million in Q3 2025, and -$40.3 million in Q2 2025.